The failure of gosuranemab could bode ill for Abbvie’s ABBV-8E12 in particular.
Casirivimab plus imdevimab could at last add a hospitalised Covid-19 patient treatment string to their bow.
But data are early, and other groups are also developing less frequent injections for wet AMD.
The data were statistically significant, but the market had been hoping for more.
But AZD7442 still has two more bites at the cherry.
A second clinical failure means that Biogen threw away $877m, but this sum will today be seen as little more than a rounding error.
But with many Western markets already saturated, it is worth wondering how important Novavax’s Covid-19 jab will become.
As Arrowhead prepares to unveil key data in alpha-1 antitrypsin deficiency, its life is made easier by Vertex’s second failure in the disease.
But, with Incyte close to market and several big players moving forward, Aclaris’s project will need to stand out from the pack.